FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212483785> ?p ?o ?g. }

• W3212483785 endingPage "1768" @default.
• W3212483785 startingPage "1768" @default.
• W3212483785 abstract "Abstract Background: Tisagenlecleucel (Kymriah) is an autologous CD19-directed CAR-T-cell therapy, approved in Aug-2017 for treating children and young adults with relapsed/refractory (r/r) acute lymphoblastic leukemia and in May-2018 for treating adults with r/r diffuse large B-cell lymphoma. Post-approval, a key goal has been to upscale and continuously improve manufacturing success and turnaround time in the commercial settings to meet the needs of a global patient population. Here we report accrued experience from our 4-year journey of optimizing the commercial tisagenlecleucel manufacturing process at the US site (Morris Plains, NJ), for faster and successful delivery to patients in the US. Methods: As reported previously, the tisagenlecleucel manufacturing process includes leukapheresis of the patient's peripheral blood mononuclear cells, enrichment and activation of T cells, transduction of the lentiviral vector containing the anti-CD19 CAR transgene, activation with anti-CD3/CD28 antibody-coated beads, expansion in cell culture, washing, and formulation of the viable cells into a cryoformulation medium. The final product is then cryopreserved, shipped back to the treatment center and infused to patients (Tyagarajan, 2020). Use of cryopreserved leukapheresis material as the starting point in commercial manufacturing is unique to tisagenlecleucel; this allows flexibility in terms of scheduling leukapheresis when a patient's health is optimal to provide T cells, and also helps offset logistical challenges (Tyagarajan, 2019). Results: As of Jun-2021, tisagenlecleucel has been manufactured for &gt;5000 patients worldwide, enabled by Novartis's significantly increased global manufacturing footprint at six sites strategically located across six countries (US, France, Switzerland, Germany, Japan and Australia) and a global treatment network of &gt;340 certified centers, including 127 centers in the US. Specifically for the US manufacturing site, between Dec-2020 and Jun-2021, 376 patients in the US had starting material available for manufacturing. Overall, the manufactured product was available for shipment for 98% of patients (shipping success rate [SSR]). The commercial manufacturing success rate (MSR) was 96%, with an out-of-specification (OOS) rate of &lt;3% and no OOS for viability. All ten OOS batches were released for infusion as benefit:risk assessment was positive. Manufacturing was cancelled for two patients upon physician's request. Immediate manufacturing capability without waiting time was available on receipt of all apheresis starting materials. The median time from start of manufacturing to shipping was 20 days. As is evident, the COVID-19 pandemic did not appear to have significantly affected the success rate or manufacturing turnaround time. These latest success metrics, reflecting significant improvements from 2018 to 2021 in MSR (69% to 96%), SSR (93% to 98%), and overall OOS rate (26% to 2%) including viability OOS rate (from 25% to 0%), are a result of upscaling the manufacturing capabilities, enhancements with hospitals focusing on optimizing apheresis collection and cryopreservation procedures, and continuous evaluation and improvement of the manufacturing process since tisagenlecleucel was first launched (Figure). Two key process and analytical improvements that were considered to have improved robustness of manufacturing and testing processes, reduced OOS rates, and minimized variability in turnaround time were introduced towards the end of 2020. Firstly, a simplified sample preparation procedure for final product cell count and viability measurement, which is more reflective of final product at infusion. Secondly, an alternate serum source (5% plasma-derived human AB serum [PD hABs]) which further improves process robustness with a trend towards improved growth and higher peak cell counts. Conclusions: Tisagenlecleucel's current global commercial manufacturing footprint and treatment network are well-positioned to meet anticipated future increase in demand for CAR-T therapies. Recent process improvements have significantly increased the MSR (to 96%) and SSR (to 98%), and immediate product availability for patients in need of CAR-T cells. Ongoing and upcoming process improvements are anticipated to further reduce the throughput time, thus allowing more patients faster access to CAR-T therapy. Figure 1 Figure 1. Disclosures Rodrigues: Novartis: Current Employment. Duran: Novartis: Current Employment. Eschgfaeller: Novartis: Current Employment. Kuzan: Novartis: Current Employment. Habucky: Novartis: Current Employment." @default.
• W3212483785 created "2021-11-22" @default.
• W3212483785 creator A5029171279 @default.
• W3212483785 creator A5043348005 @default.
• W3212483785 creator A5045926117 @default.
• W3212483785 creator A5050220593 @default.
• W3212483785 creator A5088188888 @default.
• W3212483785 date "2021-11-05" @default.
• W3212483785 modified "2023-09-30" @default.
• W3212483785 title "Optimizing Commercial Manufacturing of Tisagenlecleucel for Patients in the US: A 4-Year Experiential Journey" @default.
• W3212483785 doi "https://doi.org/10.1182/blood-2021-144897" @default.
• W3212483785 hasPublicationYear "2021" @default.
• W3212483785 type Work @default.
• W3212483785 sameAs 3212483785 @default.
• W3212483785 citedByCount "7" @default.
• W3212483785 countsByYear W32124837852022 @default.
• W3212483785 countsByYear W32124837852023 @default.
• W3212483785 crossrefType "journal-article" @default.
• W3212483785 hasAuthorship W3212483785A5029171279 @default.
• W3212483785 hasAuthorship W3212483785A5043348005 @default.
• W3212483785 hasAuthorship W3212483785A5045926117 @default.
• W3212483785 hasAuthorship W3212483785A5050220593 @default.
• W3212483785 hasAuthorship W3212483785A5088188888 @default.
• W3212483785 hasConcept C10205521 @default.
• W3212483785 hasConcept C203014093 @default.
• W3212483785 hasConcept C2777371436 @default.
• W3212483785 hasConcept C28328180 @default.
• W3212483785 hasConcept C2908647359 @default.
• W3212483785 hasConcept C54355233 @default.
• W3212483785 hasConcept C71924100 @default.
• W3212483785 hasConcept C86803240 @default.
• W3212483785 hasConcept C99454951 @default.
• W3212483785 hasConceptScore W3212483785C10205521 @default.
• W3212483785 hasConceptScore W3212483785C203014093 @default.
• W3212483785 hasConceptScore W3212483785C2777371436 @default.
• W3212483785 hasConceptScore W3212483785C28328180 @default.
• W3212483785 hasConceptScore W3212483785C2908647359 @default.
• W3212483785 hasConceptScore W3212483785C54355233 @default.
• W3212483785 hasConceptScore W3212483785C71924100 @default.
• W3212483785 hasConceptScore W3212483785C86803240 @default.
• W3212483785 hasConceptScore W3212483785C99454951 @default.
• W3212483785 hasIssue "Supplement 1" @default.
• W3212483785 hasLocation W32124837851 @default.
• W3212483785 hasOpenAccess W3212483785 @default.
• W3212483785 hasPrimaryLocation W32124837851 @default.
• W3212483785 hasRelatedWork W1506200166 @default.
• W3212483785 hasRelatedWork W1995515455 @default.
• W3212483785 hasRelatedWork W2048182022 @default.
• W3212483785 hasRelatedWork W2080531066 @default.
• W3212483785 hasRelatedWork W2094095046 @default.
• W3212483785 hasRelatedWork W2748952813 @default.
• W3212483785 hasRelatedWork W2899084033 @default.
• W3212483785 hasRelatedWork W3031052312 @default.
• W3212483785 hasRelatedWork W3032375762 @default.
• W3212483785 hasRelatedWork W3108674512 @default.
• W3212483785 hasVolume "138" @default.
• W3212483785 isParatext "false" @default.
• W3212483785 isRetracted "false" @default.
• W3212483785 magId "3212483785" @default.
• W3212483785 workType "article" @default.